Ironwood Investment Counsel LLC cut its position in Johnson & Johnson (NYSE:JNJ) by 14.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 64,725 shares of the company’s stock after selling 10,592 shares during the period. Johnson & Johnson accounts for 3.4% of Ironwood Investment Counsel LLC’s holdings, making the stock its 5th largest position. Ironwood Investment Counsel LLC’s holdings in Johnson & Johnson were worth $8,415,000 at the end of the most recent quarter.
Several other large investors have also recently modified their holdings of JNJ. Harding Loevner LP acquired a new stake in shares of Johnson & Johnson in the second quarter worth approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its position in Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after buying an additional 200 shares in the last quarter. Lenox Wealth Advisors Inc. lifted its position in Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after buying an additional 5 shares in the last quarter. IHT Wealth Management LLC lifted its position in Johnson & Johnson by 46.4% during the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after buying an additional 3,467 shares in the last quarter. Finally, Mountain Capital Investment Advisors Inc purchased a new position in Johnson & Johnson during the second quarter worth approximately $124,000. 65.71% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Johnson & Johnson (JNJ) opened at $146.86 on Wednesday. Johnson & Johnson has a 1 year low of $110.76 and a 1 year high of $148.06. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $391,587.16, a price-to-earnings ratio of 25.50, a price-to-earnings-growth ratio of 2.75 and a beta of 0.80.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the Zacks’ consensus estimate of $1.80 by $0.10. The company had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.68 earnings per share. equities research analysts expect that Johnson & Johnson will post 7.28 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be issued a $0.84 dividend. The ex-dividend date is Monday, February 26th. This represents a $3.36 annualized dividend and a dividend yield of 2.29%. Johnson & Johnson’s dividend payout ratio is presently 58.33%.
A number of equities analysts recently commented on JNJ shares. Jefferies Group lifted their price objective on Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a research report on Monday, October 16th. UBS Group reiterated a “buy” rating and set a $148.00 price objective on shares of Johnson & Johnson in a research report on Saturday, September 30th. Cowen set a $147.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a research report on Friday, October 6th. Citigroup lifted their price objective on Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a research report on Monday, October 23rd. Finally, Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $147.14 price objective on the stock in a research report on Wednesday, December 20th. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $145.94.
COPYRIGHT VIOLATION WARNING: “Johnson & Johnson (JNJ) is Ironwood Investment Counsel LLC’s 5th Largest Position” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/17/johnson-johnson-jnj-is-ironwood-investment-counsel-llcs-5th-largest-position.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.